Core Viewpoint - The company, Furui Co., Ltd. (stock code: 300049), is forecasting a significant decline in net profit for the first half of 2025 compared to the same period in 2024, with expected profits ranging from 50 million to 60 million yuan, representing a year-on-year decrease of 20% to 34% [2]. Group 1: Financial Performance - The net profit attributable to shareholders is projected to be between 50 million and 60 million yuan, down from 75.36 million yuan in the same period last year, indicating a decline of 20% to 34% [2]. - The net profit after deducting non-recurring gains and losses is expected to be between 51.5 million and 61.5 million yuan, compared to 74.46 million yuan in the previous year, reflecting a decrease of 17% to 31% [2]. - The company anticipates a net profit of approximately 75 million to 85 million yuan after excluding the impact of stock incentive expenses and exchange losses, which would represent a year-on-year growth of about 5% to 19% [7]. Group 2: Business Overview - Furui Co., Ltd. specializes in the research, development, production, and sales of medical devices and treatments for liver diseases, with a focus on the compound tortoise shell soft liver tablet, the first anti-liver fibrosis drug approved by the National Medical Products Administration [4][5]. - The company reported a revenue of 283 million yuan from its proprietary drug business in 2024, marking a year-on-year increase of 44.31% [5]. - The medical device segment has shown growth, with sales revenue expected to be between 470 million and 490 million yuan, reflecting an increase of approximately 11% to 16% compared to the previous year [7]. Group 3: Development and Services - The company has developed and sells the FibroScan series of liver fibrosis diagnostic instruments and the FibroMeter series of blood testing analysis tools, which are recognized for their innovative non-invasive detection technology [8]. - Furui Co., Ltd. provides chronic disease management services for liver disease patients through its internet hospital, establishing a comprehensive and personalized healthcare management platform [8]. - The company is also involved in software development, IT consulting services, and real estate operations, diversifying its business portfolio [8].